|
|
|
|
|
|
Sponsors and Collaborators: |
University of Alabama at Birmingham Janssen Pharmaceutica N.V., Belgium |
Information provided by: | University of Alabama at Birmingham |
ClinicalTrials.gov Identifier: | NCT00204347 |
The objective of Study A is to evaluate the efficacy of risperidone on the 4 behavioral dimensions of Berderline Personality Disorder (BPD)in an open label trial:mood swings, impulsivity, thing difficulties and disturbed relationships. The secondary objective of this study (Study B)is to validate a self-report measure of clinical symptoms specific to the treatment of patients with BPD, the UAB Borderline Rating Scale(BRS).
Condition | Intervention | Phase |
Borderline Personality Disorder |
Drug: risperidone |
Phase IV |
MedlinePlus related topics: | Personality Disorders |
ChemIDplus related topics: | Risperidone |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS) |
Estimated Enrollment: | 20 |
Study Start Date: | July 2003 |
Estimated Study Completion Date: | October 2007 |
Study A: An open-label, prospective trial of the efficacy and safety of risperidone in the treatment of BPD.The study is 8 weeks in duration, with a screening visit and follow-up visits at the end of Weeks 1,2,3,4,6, and 8. 20 female patients, 19 years or older will be recruited. A full medical and psychiatric history will be taken and a physical exam will be performed by a sstudy physician. A psychosocial assessment will be conducted during the screen.
Study B: The ofjective is to validate the UAB BRS by administering the BRS and other neuropsychological instruments as repeated measures over a 6 week period to 40 patients with BPD.
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |||||
University of Alabama at Birmingham | |||||
Birmingham, Alabama, United States, 35205 |
University of Alabama at Birmingham |
Janssen Pharmaceutica N.V., Belgium |
Principal Investigator: | Celia T. Huston, PhD | University of Alabama at Birmingham |
Study ID Numbers: | RIS-DED-WTJ |
First Received: | September 13, 2005 |
Last Updated: | February 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00204347 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|